Company profilePharmaceutical#132 of 1,318 in Pakistan✓ No DRAP alerts

Searle IV Solutions (Pvt) Ltd.

Pharmaceutical company · 127 brands · 95 molecules

Ranked #151 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

127 registered products 54 pharmaceutical brands 95 distinct molecules 0 DRAP alerts

Company overview

127
registered products
54
pharmaceutical brands
95
distinct molecules
3
therapeutic classes
0
DRAP alerts

Searle IV Solutions (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 127 product registrations across 95 distinct molecules. It is the 132nd largest registrant in Pakistan by product count, and ranks 151st of 213 in Other Beta-Lactam, Cephalosporins & Penems. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Antiinflammatory And Antirheumatic Products. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Searle

37 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

36
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202636

Top molecules by brand count

Ceftriaxone4 brands
Linezolid4 brands
Azithromycin4 brands
Cefotaxime4 brands
Ondansetron3 brands
Chloroquine3 brands
Omeprazole3 brands

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 1Antiinflammatory And Antirheumatic Products · 1Pain Management · 1

Conditions treated

Pain Killers · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official137 products · Rs 16.46 – Rs 30,876.73
Servaid1 products · Rs 265.98 – Rs 265.98
Median across source: Rs 265.98

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.27 shared molecules
Pharmasol (Pvt) Ltd.25 shared molecules
SEARLE PAKISTAN (PVT.) LTD.24 shared molecules
NEUTRO PHARMA (PVT) LTD.24 shared molecules
MEDISAVE PHARMACEUTICALS23 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 130 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
NABIQASIM INDUSTRIES (PVT) LTD. holds 187 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
Pharmasol (Pvt) Ltd. holds 105 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant

Get the full profile for Searle

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.